VIDEO: AHA presentations provide updates on SGLT2 inhibitors in HF
Click Here to Manage Email Alerts
In this video, Javed Butler, MD discusses research on SGLT2 inhibitors presented at the American Heart Association Scientific Sessions.
Butler, the Patrick H. Lehan Chair in Cardiovascular Research, professor and chairman of the department of medicine at the University of Mississippi Medical Center, discussed research from the CHIEF-HF trial — assessing canagliflozin (Invokana, Janssen) in patients with HF — which showed “pretty significant” quality of life improvements in participants. Butler said in addition to the positive findings, the trial was also “special” because it was conducted remotely.
Butler also discussed findings from the EMPULSE trial assessing empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) in hospitalized adults with acute HF and secondary analyses from the EMPEROR-Preserved trial examining empagliflozin in patients with HF with preserved ejection fraction.
“Lots of heart failure data, lots of excitement, [a] lot going on,” he said.
References:
Anker SD, et al. Hot Line: EMPEROR-Preserved/EMPEROR-Pooled. Presented at:
Spertus J, et al. LBS.05. Building on the Foundations of Treatment: Advances in Heart Failure Therapy.
Voors A, et al. LBS.05. Building on the Foundations of Treatment: Advances in Heart Failure Therapy. All presented at: American Heart Association Scientific Sessions; Nov. 13-15, 2021 (virtual meeting).
Collapse
Read more about
Click Here to Manage Email Alerts